Login to Your Account



Genentech Hits Consensus, But Avastin Sales Trouble Analysts

By Karen Pihl-Carey


Wednesday, January 12, 2005
While Genentech Inc. logged a 43 percent jump in total product sales for 2004, analysts scrutinized the company's sales of Avastin, calling them modest and lethargic at best. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription